SparingVision Reaches Final Dose Escalation Step in PRODYGY Trial with SPVN06 for retinitis pigmentosa
The trial has now progressed to the final dose cohort of the dose-escalation phase (Part 1).
- The trial has now progressed to the final dose cohort of the dose-escalation phase (Part 1).
- SPVN06 is a breakthrough gene therapy approach aimed at stopping or slowing disease progression in patients affected by rod-cone dystrophy, (RCD), regardless of their genetic background.
- SparingVision is initially focusing on mid-stage RP, one of the leading inherited causes of blindness globally.
- This progress of the PRODYGY trial to the third cohort at the highest dose of SPVN06 follows an earlier positive recommendation from the DSMB to dose the second cohort at the medium dose in August 2023.